Nisar Areeba, Ahmed Zubair, Yuan Hsiangkuo
Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Biomedicines. 2023 Feb 15;11(2):569. doi: 10.3390/biomedicines11020569.
Migraine, a primary headache disorder involving a dysfunctional trigeminal vascular system, remains a major debilitating neurological condition impacting many patients' quality of life. Despite the success of multiple new migraine therapies, not all patients achieve significant clinical benefits. The success of CGRP pathway-targeted therapy highlights the importance of translating the mechanistic understanding toward effective therapy. Ongoing research has identified multiple potential mechanisms in migraine signaling and nociception. In this narrative review, we discuss several potential emerging therapeutic targets, including pituitary adenylate cyclase-activating polypeptide (PACAP), adenosine, δ-opioid receptor (DOR), potassium channels, transient receptor potential ion channels (TRP), and acid-sensing ion channels (ASIC). A better understanding of these mechanisms facilitates the discovery of novel therapeutic targets and provides more treatment options for improved clinical care.
偏头痛是一种涉及三叉神经血管系统功能失调的原发性头痛疾病,仍然是一种严重影响许多患者生活质量的使人衰弱的神经系统疾病。尽管多种新型偏头痛治疗方法取得了成功,但并非所有患者都能获得显著的临床益处。靶向降钙素基因相关肽(CGRP)通路疗法的成功凸显了将机制理解转化为有效治疗方法的重要性。正在进行的研究已经确定了偏头痛信号传导和痛觉感受中的多种潜在机制。在这篇叙述性综述中,我们讨论了几种潜在的新兴治疗靶点,包括垂体腺苷酸环化酶激活多肽(PACAP)、腺苷、δ-阿片受体(DOR)、钾通道、瞬时受体电位离子通道(TRP)和酸敏感离子通道(ASIC)。对这些机制的更好理解有助于发现新的治疗靶点,并为改善临床护理提供更多治疗选择。